Pharming N : Group announces development plans for leniolisib for additional primary immunodeficiencies (PIDs) - Form 6-K -December 15, 2023 at 06:20 am EST

Document




UNITED STATES


SECURITIES AND EXCHANGE COMMISSION


Washington, D.C. 20549










...

Related Keywords

Canada ,United Kingdom ,Australia ,Netherlands ,Amsterdam ,Noord Holland ,Israel ,United States ,London ,City Of ,Washington ,Japan ,America ,Gulbu Uzel ,Ethan Metelenis ,Anurag Relan ,Heather Robertson ,V Koneti Rao ,Michael Levitan ,Pharming Groupnv ,Commission File Number ,Pharming Group ,Investor Relations Corporate Communications ,Lifespring Life Sciences Communication ,National Institutes Of Health ,Nasdaq ,Exchange Commission ,Drug Administration ,Securities Exchange ,National Institute Of Allergy ,Senior Research Physician ,Clinical Immunodeficiency Program ,Vp Investor Relations Corporate Communications ,Linkedin ,Beth Israel Lahey Health ,File Number ,Exact Name ,Its Charter ,Regulationst Rule ,Securities Exchange Act ,Sijmen De Vries ,National Institute ,Infectious Diseases ,National Institutes ,Primary Immune Deficiency Clinic ,Jocelyn Farmer ,Chief Medical Officer ,Activated Phosphoinositide ,North America ,Middle East ,Annual Report ,Allergy Clin ,Rev Allergy ,Clinical Immunology ,Investor Relations ,Corporate Communications Manager ,Spring Life Sciences Communication ,Markets ,